MADISON,
Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the company's
Radixact SynC™ System and CyberKnife® S7™ System have
been approved by the Chinese National Medical Products
Administration (NMPA). With these approvals medical care teams can
provide patients in China the most
advanced Accuray radiation therapy solutions. The CyberKnife S7
System is the latest generation CyberKnife platform and the
introduction of the Radixact SynC System marks the first approval
in the country for the ClearRT® kVCT imaging and
Synchrony® real-time adaptive delivery technology on the
Radixact System.
"We couldn't be more pleased about the timing of these approvals
that come on the heels of the introduction of our Tomo C System,
developed for the unique needs of the largest segment of the market
in China," said Suzanne Winter, president and CEO of
Accuray.
Continued Ms. Winter, "I am thrilled with the customer adoption
of the Tomo C System since its approval last year. Now with our
latest CyberKnife S7 and Radixact SynC Systems, the Accuray teams
in China can offer a powerful
product portfolio to address clinicians' varied requirements.
Currently, the number of people needing radiotherapy treatments in
China far outweighs the capacity
for treatment. In fact, it is estimated that approximately 2,000
systems will be needed over the next five years1. These
approvals further advance our growth strategy of expanding patient
access by offering compelling and unique solutions to enable more
people to receive treatment with our potentially life-saving
technology."
The Radixact SynC and CyberKnife S7 Systems are designed to
improve the radiation treatment experience while making high
precision care available for more patients.
Radixact SynC System: Cancer Treatment that Revolves Around
the Patient
The Radixact SynC System's helical design
enables the delivery of precise doses of radiation continuously
from multiple 360-degree rotations around the patient, providing
greater control of the radiation dose so it conforms precisely to
the tumor and minimizes dose to healthy tissue.
The Radixact SynC System is currently the only helical delivery
device in China with Synchrony
real-time target tracking and correction technology. The addition
of Synchrony to the Radixact System is designed to facilitate more
precise delivery of radiation to tumors that move as a result of
bodily processes or patient movement. The Accuray proprietary
Synchrony technology is unique in using image guidance during
radiation treatment delivery to detect motion and automatically
adapt and synchronize the radiation beam in real-time with the
movement of the target.
ClearRT is a helical kVCT fan-beam integrated imaging solution
for the Radixact System, providing clinicians with an option for
easily, quickly and cost effectively acquiring diagnostic-like
quality CT images. These images enable high confidence in the
patient set-up and registration steps that form the basis of
radiation therapy treatment delivery and monitoring and are key to
the successful treatment of organ-confined tumors, locally advanced
tumors and metastatic tumors.
The CyberKnife® S7™ System: Robotic Precision that
Makes Treatment Possible in just 1 to 5 Out-Patient
Sessions
The latest generation CyberKnife platform delivers
the extremely precise radiation treatments clinicians have come to
expect with the system, combined with the speed they need to
support their busy practices. The CyberKnife S7 System is a
robotic, non-invasive radiosurgery device capable of treating
cancerous and benign tumors throughout the body with
sub-millimetric accuracy in as little as 15 minutes, enabling
medical care teams to provide highly precise radiation treatments
to more patients, every day.
The precision and accuracy of the CyberKnife System enables
clinical teams to deliver ultra-hypofractionated radiation therapy
― very high doses of precisely targeted radiation are delivered in
a few days versus conventional fractionation where treatments often
require 30-40 sessions. The entire procedure with the CyberKnife
System is typically completed in just 1 to 5 out-patient sessions,
enabling those people who are unable to travel a month or more for
care to receive radiation therapy treatments.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Madison,
Wisconsin, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations and goals
regarding new products, services and innovations, expectations
regarding our joint venture, patient experiences and patient
outcomes. These risks and uncertainties include, but are not
limited to, the effect of the global macroeconomic environment on
the operations of the company and those of its customers and
suppliers; disruptions to our supply chain, including increased
logistics costs; the company's ability to achieve widespread market
acceptance of its products; the company's ability to realize the
expected benefits of the China
joint venture and other partnerships; risks inherent in
international operations; the company's ability to maintain or
increase its gross margins on product sales and services; delays in
regulatory approvals or the development or release of new
offerings; the company's ability to meet the covenants under its
credit facilities; the company's ability to convert backlog to
revenue; and such other risks identified under the heading "Risk
Factors" in the company's Quarterly Report on Form 10-Q, filed with
the Securities and Exchange Commission (the "SEC") on November 6, 2024, and as updated periodically
with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
1 Notice of the National Health Commission on the
issuance of the "14th Five-Year Plan" large-scale medical equipment
configuration plan
Notice of the National Health Commission on Issuing the "14th
Five-Year Plan" for the Allocation of Large-scale Medical
Equipment_Documents of the State Council_Chinese Government
Network
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-announces-china-national-medical-products-administration-approval-of-the-radixact-sync-and-cyberknife-s7-systems-expands-on-the-china-product-portfolio-that-includes-the-recently-approved-tomo-c-system-302349676.html
SOURCE Accuray Incorporated